<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{border-left: none;background-color:#ffffff;}.ritz .waffle .s6{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s9{border-right: none;background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#1155cc;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s8{border-right: none;background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{border-left: none;border-right: none;background-color:#ffffff;}.ritz .waffle .s7{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1768999354C0" style="width:100px;" class="column-headers-background">A</th><th id="1768999354C1" style="width:100px;" class="column-headers-background">B</th></tr></thead><tbody><tr style="height: 20px"><th id="1768999354R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Uterine Artery Embolisation</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1768999354R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="1768999354R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">UAE for the Management of Fibroids</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">As effective as surgery for symptom control over 5 years</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">80-90% will be asymptomatic or have significantly improved symptoms at 1 year</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">1 in 3 women require second intervention by 5 years, compared with 4% with surgery</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Contraindicated in women with PID or who are pregnant</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Women need to accept risk of requiring hysterectomy which may be necessary in 2.9% of cases.</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Relative contraindication: intention to have future pregnancy due to diminshed ovarian reserve</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1768999354R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Pregnancy Outcomes</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1768999354R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1498px;left:-1px">Higher rates of c-section, PPH and 1st trimester miscarriage have been suggested by studies but it should be noted these studies may have had significant cofounding factors such as control groups having smaller fibroids than treatment groups.</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1768999354R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s6" dir="ltr">Complications</td><td></td></tr><tr style="height: 20px"><th id="1768999354R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s7" dir="ltr">Early</td><td></td></tr><tr style="height: 20px"><th id="1768999354R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">Post-embolisation syndrome (pain, nausea, fever and malaise, raised inflammatory markers) - usually self limiting and subsides within 10 to 14 days of the procedure</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1768999354R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s8 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Late (&gt;30 days post-op)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1768999354R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Vaginal discharge (16% at 12months)</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Expulsion fibroid material (10%)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1768999354R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Endometritis (0.5%)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1768999354R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Amenorrhoea (age dependent &lt;1% in women under 40 years old)</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Change in sexual function (worse in 10%, improved in 26%, unchanged in most)</div></td><td class="s3"></td></tr><tr style="height: 20px"><th id="1768999354R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s5" dir="ltr"></td><td class="s5" dir="ltr"></td></tr><tr style="height: 20px"><th id="1768999354R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s5" dir="ltr">Source:</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">RCOG Clinical recommendations on use of UAE 2013</div></td></tr><tr style="height: 20px"><th id="1768999354R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td></td><td class="s9 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px"><a target="_blank" href="https://www.rcog.org.uk/globalassets/documents/guidelines/23-12-2013_rcog_rcr_uae.pdf">https://www.rcog.org.uk/globalassets/documents/guidelines/23-12-2013_rcog_rcr_uae.pdf</a></div></td></tr></tbody></table></div>